logo
#

Latest news with #PraveenGupta

Premas Life Sciences and Sphere Bio Unite to Advance Single-Cell Research in South Asia
Premas Life Sciences and Sphere Bio Unite to Advance Single-Cell Research in South Asia

Business Standard

time06-05-2025

  • Business
  • Business Standard

Premas Life Sciences and Sphere Bio Unite to Advance Single-Cell Research in South Asia

India PR Distribution New Delhi [India], May 6: Premas Life Sciences Pvt. Ltd. (PLS), a pioneering enabler of life science innovations in India, has announced a strategic collaboration with Sphere Bio, a global leader in picodroplet-based microfluidic technologies for functional single-cell analysis. This partnership represents a significant leap in bringing transformative, next-generation platforms to scientists and researchers in India and Bangladesh. The collaboration is rooted in a shared vision: empowering biopharma, biotech, and academic communities with cutting-edge tools that accelerate discovery and drive impactful science. With this alliance, Premas will bring Sphere Bio's high-performance solutions - including their flagship Cyto-Mine® platform and a growing assay portfolio - closer to researchers in South Asia, supported by localized technical expertise and seamless implementation support. Sphere Bio, formerly known as Sphere Fluidics, is widely recognized for its innovations in single-cell and picodroplet microfluidics. Their technologies enable ultra-high-throughput analysis, sorting, and isolation of individual cells - critical for applications such as antibody discovery, cell line development, and advanced cell therapy research. These platforms are currently used by leading pharma companies and research institutions around the world to enhance the speed and accuracy of biologic development. For Premas Life Sciences, this partnership is a natural extension of its mission to democratize access to advanced life science tools. Over the last 18 years, PLS has built a strong legacy of introducing globally benchmarked technologies to India's scientific ecosystem - spanning genomics, proteomics, bioinformatics, and diagnostics. Their ability to not only introduce but also embed technologies through technical training, application support, and long-term scientific partnerships makes them uniquely positioned to amplify the impact of Sphere Bio's offerings. "India is entering a new era of biomedical innovation, with increased investments in biosimilars, vaccines, and cell and gene therapies. This collaboration with Sphere Bio allows us to deliver the kind of scientific capabilities that can transform how research is done in this region--faster, more precisely, and with greater reproducibility. With the government's strong push through initiatives like the Bio-E3 policy, PRIP scheme, and its vision for bio foundries, we believe technologies like Sphere Bio's Cyto-Mine® will play a crucial role in accelerating antibody discovery and cell line development, further strengthening the 'Made in India' biotech ecosystem. We're excited to co-create a future where access to such platforms is not a barrier but a baseline." said Praveen Gupta, Managing Director of Premas Life Sciences. Sphere Bio echoed this optimism. "We see South Asia as a region with enormous scientific potential. Our partnership with Premas is about more than market access - it's about long-term impact. Premas brings deep local understanding, technical know-how, and a genuine commitment to enabling discovery. Together, we aim to catalyse the next wave of breakthroughs in biologics and personalized medicine." said Dale Levitzke, CEO of Sphere Bio "Our partnership with Premas Life Sciences is a key milestone in our mission to make cutting-edge single-cell technologies more accessible across the APAC region. India and Bangladesh represent rapidly growing innovation hubs, and we see immense potential in empowering local researchers with tools that meet global standards. Premas brings deep market understanding, strong scientific engagement, and a track record of successful technology integration--making them an ideal partner to drive regional adoption and impact." said Jay Manikandan, VP Commercial (APAC), Sphere Bio This alliance comes at a pivotal time, as the biotech landscape in India and Bangladesh rapidly evolves with government backing, rising R & D investment, and a growing scientific workforce. As demand for next-gen therapeutics increases, so does the need for high-resolution, scalable tools--precisely what Sphere Bio delivers. Together, Premas and Sphere Bio are building a scientific bridge between global innovation and regional potential. Beyond product access, the partnership offers localized support, training, and tailored solutions aligned with international standards. It sets a new benchmark for how advanced technologies can be effectively introduced and scaled in emerging biotech markets.

World Malaria Day 2025: Do you know about cerebral malaria; the deadliest form that affects the brain?
World Malaria Day 2025: Do you know about cerebral malaria; the deadliest form that affects the brain?

Hindustan Times

time25-04-2025

  • Health
  • Hindustan Times

World Malaria Day 2025: Do you know about cerebral malaria; the deadliest form that affects the brain?

World Malaria Day 2025: Every year, World Malaria Day is observed on April 25 to discuss and discover treatment and precautions that can help in preventing malaria from spreading. This day helps in creating awareness about the health complications of the disease and the lifestyle habits that can help in staying safe. Also read | World Malaria Day 2025: Know how malaria can affect your heart We cannot possibly discuss the harmful effects of malaria without bringing up its deadliest form, that affects the brain cells. Known as cerebral malaria, it occurs when infected red blood cells block small blood vessels in the brain, leading to inflammation, swelling, and damage to brain tissue. In an interview with HT Lifestyle, Dr. Praveen Gupta, principal director and chief of neurology, Fortis Memorial Research Institute, Gurugram explained the causes, symptoms and fatality of the disease. Cerebral malaria is caused by the bite of a female Anopheles mosquito carrying P. falciparum. Once in the bloodstream, the parasite multiplies inside red blood cells. In severe cases, these infected cells adhere to the walls of cerebral blood vessels, disrupting blood flow and triggering inflammation. Symptoms typically develop within 7–10 days of infection. Key signs of cerebral malaria include: Diagnosis of cerebral malaria involves blood tests to detect malaria parasites, often through microscopy or rapid diagnostic tests (RDTs). Brain imaging and lumbar puncture may be used to rule out other neurological conditions like meningitis. Cerebral malaria is a medical emergency. Immediate treatment with intravenous antimalarial drugs such as artesunate or quinine is crucial. Supportive care, such as managing seizures, fluids, and oxygen, can also improve survival. Patients typically require intensive care. Also read | World Malaria Day 2024: 10 warning signs of the vector-borne disease you must know Prevention strategies focus on avoiding mosquito bites and controlling the spread of malaria. This includes: Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store